Oestrogen receptor alpha in papillary thyroid carcinoma: association with clinical features and BRAFV600E mutation

被引:4
作者
Liu, Shiyang [1 ]
Jiao, Bo [2 ]
Li, Shuyu [1 ]
Zhao, Lu [1 ]
Zheng, Weihong [1 ]
Wang, Kun [1 ]
Xu, Jing [1 ]
Tian, Yao [1 ]
Liu, Chenguang [1 ]
Gui, Zhengwei [1 ]
Zhang, Lin [1 ]
机构
[1] Huazhong Univ Sci & Technol, Dept Thyroid & Breast Surg, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Peoples R China
[2] Huazhong Univ Sci & Technol, Dept Anesthesiol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
关键词
ESR1; ER alpha; BRAF(V600E) mutation; BRAF(V600E) protein; papillary thyroid cancer; EXPRESSION; CANCER; GROWTH; IMPACT;
D O I
10.1093/jjco/hyab058
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Papillary thyroid cancer cells can express oestrogen receptor alpha, which is encoded by the ESR1 gene and may bind to oestrogen to induce the occurrence and development of papillary thyroid cancer. The BRAF(V600E) mutation is also an important biomarker for the occurrence and progression of papillary thyroid cancer. However, the association between the BRAF(V600E) mutation and oestrogen receptor alpha expression has not been identified. This study aims to investigate the association between ESR1 expression and the BRAF(V600E) mutation and its clinical significance. Methods: Oestrogen receptor alpha and BRAF(V600E) proteins were detected by immunohistochemical staining of formalin-fixed paraffin-embedded thyroid tissues from 1105 patients with papillary thyroid cancer at our institution. Messenger RNA expression counts of ESR1 and clinicopathologic information were obtained from The Cancer Genome Atlas database. Results: Oestrogen receptor alpha protein expression was significantly associated with BRAF(V600E) protein. The positive rate of oestrogen receptor alpha protein in papillary thyroid cancer patients was significantly higher in males, younger patients and patients with the multifocal type. In papillary thyroid cancer patients with positive BRAF(V600E) protein, oestrogen receptor alpha expression was significantly correlated with central lymph node metastasis. Data from the The Cancer Genome Atlas database also suggested that the ESR1 messenger RNA level was associated with the BRAF(V600E) mutation. Furthermore, classification analysis performed according to a tree-based classification method demonstrated that higher ESR1 messenger RNA expression indicated poorer overall survival in papillary thyroid cancer patients with the BRAF(V600E) mutation. Conclusions: The percentage of BRAF(V600E) mutations is increased in patients with higher ESR1 messenger RNA levels, and the BRAF(V600E) protein might be co-expressed with oestrogen receptor alpha, which could be an indicator of cervical lymph node metastasis and poor overall survival in patients with papillary thyroid cancer.
引用
收藏
页码:1051 / 1058
页数:8
相关论文
共 50 条
  • [21] BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis
    Li, Fei
    Chen, Guangqi
    Sheng, Chunjun
    Gusdon, Aaron M.
    Huang, Yueye
    Lv, Zhongwei
    Xu, Huixiong
    Xing, Mingzhao
    Qu, Shen
    [J]. ENDOCRINE-RELATED CANCER, 2015, 22 (02) : 159 - 168
  • [22] BRAFV600E Mutation in Papillary Thyroid Carcinoma: Significant Association with Node Metastases and Extra Thyroidal Invasion
    Chakraborty, Avik
    Narkar, Archana
    Mukhopadhyaya, Rita
    Kane, Shubhada
    D'Cruz, Anil
    Rajan, M. G. R.
    [J]. ENDOCRINE PATHOLOGY, 2012, 23 (02) : 83 - 93
  • [23] Concomitant BRAFV600E Mutation and RET/PTC Rearrangement Is a Frequent Occurrence in Papillary Thyroid Carcinoma
    Guerra, Anna
    Zeppa, Pio
    Bifulco, Maurizio
    Vitale, Mario
    [J]. THYROID, 2014, 24 (02) : 254 - 259
  • [24] Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma
    Wei, Xiaojing
    Wang, Xiaodong
    Xiong, Jie
    Li, Chen
    Liao, Yixuan
    Zhu, Yongjun
    Mao, Jingxin
    [J]. BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [25] BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic
    Sykorova, V.
    Dvorakova, S.
    Ryska, A.
    Vcelak, J.
    Vaclavikova, E.
    Laco, J.
    Kodetova, D.
    Kodet, R.
    Cibula, A.
    Duskova, J.
    Hlobilkova, A.
    Astl, J.
    Vesely, D.
    Betka, J.
    Hoch, J.
    Smutny, S.
    Cap, J.
    Vlcek, P.
    Novak, Z.
    Bendlova, B.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2010, 33 (05) : 318 - 324
  • [26] The BRAFV600E mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
    Walczyk, Agnieszka
    Kowalska, Aldona
    Kowalik, Artur
    Sygut, Jacek
    Wypiorkiewicz, Elzbieta
    Chodurska, Renata
    Pieciak, Liliana
    Gozdz, Stanislaw
    [J]. CLINICAL ENDOCRINOLOGY, 2014, 80 (06) : 899 - 904
  • [27] Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAFV600E Mutation
    Lee, Seung Eun
    Hwang, Tae Sook
    Choi, Yoon-La
    Kim, Wook Youn
    Han, Hye Seung
    Lim, So Dug
    Kim, Wan-Seop
    Yoo, Young Bum
    Kim, Suk Kyeong
    [J]. THYROID, 2017, 27 (06) : 802 - 810
  • [28] Association Between Obesity and BRAFV600E Mutation Status in Patients with Papillary Thyroid Cancer
    Jandee Lee
    Cho Rok Lee
    Cheol Ryong Ku
    Sang-Wook Kang
    Jong Ju Jeong
    Dong Yeob Shin
    Kee-Hyun Nam
    Sang Geun Jung
    Eun Jig Lee
    Woong Youn Chung
    Young Suk Jo
    [J]. Annals of Surgical Oncology, 2015, 22 : 683 - 690
  • [29] Is BRAFV600E mutation a marker for central nodal metastasis in small papillary thyroid carcinoma?
    Lang, Brian Hung-Hin
    Chai, Young Jun
    Cowling, Benjamin J.
    Min, Hye Sook
    Lee, Kyu Eun
    Youn, Yeo-Kyu
    [J]. ENDOCRINE-RELATED CANCER, 2014, 21 (02) : 285 - 295
  • [30] BRAFv600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma
    Jing Fan-jing
    Liang Jun
    Liang Zhi-yong
    Meng Chao
    Long Wen
    Li Xiao-yi
    Lin Yan-song
    [J]. CHINESE MEDICAL JOURNAL, 2013, 126 (16) : 3013 - 3018